Serum estradiol level and risk of breast cancer during treatment with raloxifene

JAMA

Volumn 287, Issue 2, 2002, Pages 216-220

  Cummings, Steven R ^a   Duong, Tu ^a   Kenyon, Emily ^a   Cauley, Jane A ^b   Whitehead, Malcolm ^c   Krueger, Kathryn A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0037045446     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.2.216     Document Type: Article

References (19)

1. A prospective study of endogenous estrogens and breast cancer in postmenopausal women
2. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk
3. Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer
4. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
5. Molecular basis of agonism and antagonism in the oestrogen receptor
6. Molecular determinants of tissue selectivity in estrogen receptor modulators
7. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
8. Tamoxifen for early breast cancer: An overview of the randomized trials
9. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
10. Indicators of lifetime estrogen exposure: Breast cancer incidence and interaction with raloxifene therapy in MORE study participants
11. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial
12. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
13. Fieller's theorem versus the delta method for significance intervals of ratios
14. Endogenous hormones and the risk of hip and vertebral fractures among older women
15. Bone mineral density and risk of breast cancer in older women: The Study of Osteoporotic Fractures
16. Bone mass and the risk of breast cancer among postmenopausal women
17. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
18. Projecting individualized probabilities of developing breast cancer for white females who are being examined an nually
19. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3 year period